Cargando…

Early Stepdown From Echinocandin to Fluconazole Treatment in Candidemia: A Post Hoc Analysis of Three Cohort Studies

BACKGROUND: There are no clear criteria for antifungal de-escalation after initial empirical treatments. We hypothesized that early de-escalation (ED) (within 5 days) to fluconazole is safe in fluconazole-susceptible candidemia with controlled source of infection. METHODS: This is a multicenter post...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moreno-García, E, Puerta-Alcalde, P, Gariup, G, Fernández-Ruiz, M, López Cortés, L E, Cuervo, G, Salavert, M, Merino, P, Machado, M, Guinea, J, García-Rodríguez, J, Garnacho-Montero, J, Cardozo, C, Peman, J, Montejo, M, Fortún, J, Almirante, B, Castro, C, Rodríguez-Baño, J, Aguado, J M, Martínez, J A, Carratalà, J, Soriano, A, Garcia-Vidal, C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Major Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8180243/ https://www.ncbi.nlm.nih.gov/pubmed/34104670 http://dx.doi.org/10.1093/ofid/ofab250

Ejemplares similares

Correction to: Early Stepdown From Echinocandin to Fluconazole Treatment in Candidemia: A Post Hoc Analysis of Three Cohort Studies
por: Moreno-García, E, et al.
Publicado: (2022)

Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and/or invasive candidiasis in nonneutropenic adult patients
por: Grau, S, et al.
Publicado: (2015)

The Effect on Mortality of Fluconazole or Echinocandins Treatment in Candidemia in Internal Medicine Wards
por: De Rosa, Francesco G., et al.
Publicado: (2015)

Correction: The Effect on Mortality of Fluconazole or Echinocandins Treatment in Candidemia in Internal Medicine Wards
Publicado: (2015)

2117. Fluconazole vs. Echinocandins as Initial Therapy for Candidemia Caused by Fluconazole-Susceptible Species in the Era of Rapid Diagnostic Testing
por: Roshdy, Danya, et al.
Publicado: (2019)

Outcomes Comparing Initial Short vs Long Course Echinocandin Therapy in Patients with Candidemia Caused by Fluconazole Susceptible Strains
por: Small-Saunders, Jennifer L, et al.
Publicado: (2017)

Factors associated with the development of septic shock in patients with candidemia: a post hoc analysis from two prospective cohorts
por: Bassetti, Matteo, et al.
Publicado: (2020)

Effect of Statin Use on Outcomes of Adults with Candidemia
por: Cuervo, Guillermo, et al.
Publicado: (2013)

146 Review of Empiric Echinocandin Therapy for Candidemia
por: Amado, Cristina, et al.
Publicado: (2014)

Evaluation of Fluconazole versus Echinocandins for Treatment of Candidemia Caused by Susceptible Common Candida Species: A Propensity Score Matching Analysis
por: Kim, Jong Hun, et al.
Publicado: (2023)

Impact of echinocandins as first-choice therapy in cardiothoracic high-risk patients with candidemia
por: Langebartels, G, et al.
Publicado: (2013)

372. Attributable Mortality of Candidemia After Introduction of Echinocandins
por: Cornely, Florian, et al.
Publicado: (2018)

Decreased echinocandin susceptibility in Candida parapsilosis causing candidemia and emergence of a pan-echinocandin resistant case in China
por: Ning, Yating, et al.
Publicado: (2022)

Development of High-Level Echinocandin Resistance in a Patient With Recurrent Candida auris Candidemia Secondary to Chronic Candiduria
por: Biagi, Mark J, et al.
Publicado: (2019)

Biomarkers of fungal infection: Expert opinion on the current situation
por: Bouza, Emilio, et al.
Publicado: (2020)

Determinants of fluconazole resistance and echinocandin tolerance in C. parapsilosis isolates causing a large clonal candidemia outbreak among COVID-19 patients in a Brazilian ICU
por: Daneshnia, Farnaz, et al.
Publicado: (2022)

Impact of the COVID-19 Pandemic on the Clinical Profile of Candidemia and the Incidence of Fungemia Due to Fluconazole-Resistant Candida parapsilosis
por: Ramos-Martínez, Antonio, et al.
Publicado: (2022)

Treatment of candidemia in a nationwide setting: increased survival with primary echinocandin treatment
por: Lausch, Karen Rokkedal, et al.
Publicado: (2018)

Factors associated with the development of ocular candidiasis and ocular prognosis with echinocandin therapy for candidemia
por: Sakai, Daiki, et al.
Publicado: (2021)

Incidence of candidemia before and after fluconazole prophylaxis implementation in a 14-bed general ICU
por: Vartzeli, P, et al.
Publicado: (2008)

Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007
por: Poikonen, Eira, et al.
Publicado: (2010)

Impact of the Disk Diffusion Test on Fluconazole De-Escalation in Patients with Candidemia
por: Tantasuwan, Suchavadee, et al.
Publicado: (2022)

Usefulness of Chromogenic Media with Fluconazole Supplementation for Presumptive Identification of Candida auris
por: Ruiz-Gaitán, Alba, et al.
Publicado: (2023)

The In Vitro Activity of Fluconazole, Amphotericin B and Echinocandins Against Cyberlindnera fabianii Planktonic Cells and Biofilms
por: Tóth, Zoltán, et al.
Publicado: (2022)

Recurrent episodes of Candidemia due to Candida glabrata, Candida tropicalis and Candida albicans with acquired echinocandin resistance
por: Grosset, Marine, et al.
Publicado: (2016)

1842. Intravenous to Oral Antibiotic Stepdown for Uncomplicated Streptococcal Bacteremia
por: Salam, Madison E, et al.
Publicado: (2022)

T2Candida(®) to guide antifungal and lengh of treatment of candidemia in a pediatric multivisceral transplant recipient
por: Falces-Romero, Iker, et al.
Publicado: (2018)

Outbreak of candidemia caused by fluconazole resistant Candida parapsilosis strains in an intensive care unit
por: Pinhati, Henrique Marconi Sampaio, et al.
Publicado: (2016)

Epidemiology of Candidemia and Fluconazole Resistance in an ICU before and during the COVID-19 Pandemic Era
por: Routsi, Christina, et al.
Publicado: (2022)

Cost-utility analysis of caspofungin and fluconazole for primary treatment of invasive candidiasis and candidemia in Ethiopia
por: Gebretekle, Gebremedhin Beedemariam, et al.
Publicado: (2022)

2116. Comparative Effectiveness of Amphotericin B, Azoles, and Echinocandins in the Treatment of Candidemia and Invasive Candidiasis: A Systematic Review and Network Meta-Analysis
por: Demir, Koray K, et al.
Publicado: (2019)

Genotyping Reveals High Clonal Diversity and Widespread Genotypes of Candida Causing Candidemia at Distant Geographical Areas
por: Guinea, Jesús, et al.
Publicado: (2020)

A Brazilian Inter-Hospital Candidemia Outbreak Caused by Fluconazole-Resistant Candida parapsilosis in the COVID-19 Era
por: Thomaz, Danilo Y., et al.
Publicado: (2022)

Candida dubliniensis candidemia in Australia.
por: Marriott, D, et al.
Publicado: (2001)

Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: protocol of a multicentre, randomised, phase III trial
por: Shaw, E, et al.
Publicado: (2015)

The impact of caspase-12 on susceptibility to candidemia
por: Rosentul, D. C., et al.
Publicado: (2011)

P1595: IFISTRATEGY: A SPANISH NATIONAL SURVEY ON STRATEGIES FOR MANAGEMENT OF INVASIVE FUNGAL INFECTION AND GUIDELINES APPLICATION IN HIGH RISK ONCO-HEMATOLOGICAL PATIENTS
por: Vallejo, C., et al.
Publicado: (2022)

Mutants with heteroresistance to amphotericin B and fluconazole in Candida
por: Claudino, A.L.R., et al.
Publicado: (2009)

Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome
por: Reboli, Annette C, et al.
Publicado: (2011)

468. Assessment of The Proportion of Hospitalized Patients (Pts) with Candidemia (C) and Invasive Candidiasis without Candidemia (IC) Who Received an Echinocandin (EC) and Were Potentially Eligible for an Earlier Hospital Discharge (HD)
por: Lodise, Thomas, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2cqqc7loihd0tn7qpi875k4f1l